Clinical Study Synopsis

Size: px
Start display at page:

Download "Clinical Study Synopsis"

Transcription

1 Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labelling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer HealthCare. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer HealthCare. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayerhealthcare.com apply to the contents of this file.

2 14 Apr 2014 Study no Page: 1 of 6 2. Synopsis Date of report: 14 Apr 2014 Study title: Randomized, open-label, parallel-group, active-controlled study of rivaroxaban in patients with acute symptomatic pulmonary embolism, with or without symptomatic deep vein thrombosis Sponsor s study number: NCT number: EudraCT number: Sponsor: Clinical phase: Study objectives: NCT Not Applicable Bayer Yakuhin III The objective of this study was to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in the treatment of pulmonary embolism (PE) and the prevention of the occurrence and the recurrence of deep vein thrombosis (DVT) or PE in Japanese patients with acute symptomatic PE with or without symptomatic DVT Test drug: Rivaroxaban (Xarelto; BAY ) Name of active ingredient(s): Rivaroxaban Dose: 15 mg twice daily (bid) for 21 days, followed by 15 mg once daily (od) Route of administration: Oral (tablet) Duration of treatment: Reference drug: Dose: Route of administration: Duration of treatment: Indication: 3, 6 and 12 months (to be determined by the investigator individually at randomization) Unfractionated heparin (UFH), Warfarin UFH: to be adjusted to maintain the activated partial thromboplastin time (aptt) prolongation (1.5 to 2.5 times the control) Warfarin: to be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5) UFH: Intravenous Warfarin: Oral UFH: 5 days or more until PT-INR values reach the target range Warfarin: 3, 6 and 12 months (to be determined by the investigator individually at randomization) Acute symptomatic pulmonary embolism

3 14 Apr 2014 Study no Page: 2 of 6 Diagnosis and main criteria for inclusion: Study design: Methodology Study center(s): Men and women 20 years of age in patients with confirmed acute symptomatic PE with or without symptomatic DVT Written informed consent Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE More than 48 hours pre-randomization treatment with therapeutic dosages of anti-coagulant treatment or more than a single dose of warfarin from the onset of the current episode of PE to randomization. Calculated creatinine clearance (CL CR ) < 30 ml/min Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk Active bleeding or high risk for bleeding contraindicating treatment with UFH or warfarin Systolic blood pressure > 180 mmhg or diastolic blood pressure > 110 mmhg Multi-center, randomized, open-label, assessor-blind, active-controlled, and parallel-group designed study This was a study to evaluate the efficacy, safety, PK and PD of rivaroxaban in the treatment of patients with acute symptomatic PE with or without symptomatic DVT for the prevention of recurrent venous thromboembolic events. 40 patients were planned to be enrolled in this study. Each patient was allocated to either of 2 groups; the rivaroxaban group or the reference group. Allocation to treatment was done centrally by interactive web response system (IWRS) and was be stratified by intended treatment duration. The decision to treat for 3, 6 or 12 months was based on the risk profile of the patient and was made by the investigator at the time of randomization. After randomization, patients allocated to rivaroxaban received rivaroxaban 15 mg bid for a total of 3 weeks followed by rivaroxaban 15 mg od. Patients allocated to the reference received dose adjusted UFH to maintain aptt prolongation (1.5 to 2.5 times the control) that corresponded to plasma heparin levels of 0.3 to 0.7 IU/mL anti-xa activity for at least 5 days in combination with warfarin (overlap 4 to 5 days) and continued with warfarin alone if the PT-INR had been 1.5 on two consecutive measurements at least 24 hours apart. The dose of warfarin was adjusted to maintain PT-INR within 1.5 to 2.5. This study consisted of Screening, Treatment Period 1 (rivaroxaban 15 mg bid or UFH/warfarin was administered in this period): Day 1 to Day 21 (±2 days), Treatment Period 2 (rivaroxaban 15 mg od or warfarin was administered in this period): Day 22 (±2 days) to Day 85 (±7 days), Day 169 (±7 days) or Day 365 (±7 days), and Follow-up visit: 30 days after the end of treatment (±7 days). At the end-of-treatment visit or at an early study medication discontinuation visit, subjects proceeded to an appropriate therapy. Until a follow-up visit, observation was continued. The study was conducted at 24 centers in Japan

4 14 Apr 2014 Study no Page: 3 of 6 Publication(s) based on the study (references): None at the time of report creation Study period: Study Start Date: 20 FEB 2012 Study Completion Date: 15 NOV 2013 Early termination No Number of subjects: Planned: Total 40 subjects: Rivaroxaban group: 32 subjects Reference (UFH + Warfarin) group: 8 subjects Analyzed: More details are given in the section on study subjects below. Criteria for evaluation Efficacy: Safety: The symptomatic VTE (composite endpoint of symptomatic DVT or symptomatic fatal or non-fatal PE). The combination of treatment-emergent major and non-major clinically relevant bleedings. Statistical methods: Substantial protocol changes: Efficacy analysis The primary efficacy analysis was performed in patients valid for intention-to-treat (ITT) analysis. For the primary efficacy endpoint, the point estimate of the incidence rate and the corresponding 2-sided 95% exact confidence interval (CI) were calculated by treatment group. The incidence of any other efficacy variables are tabulated and stratified by treatment group. The ITT on treatment analysis and the per-protocol (PP) analysis was performed as supportive analysis. Safety analysis The safety analysis was performed in the population of subjects valid for safety analysis. For the main safety endpoint, the point estimate of the incidence rate and the corresponding 2-sided 95% exact CI were calculated for each treatment. The incidences of any other safety variables were tabulated and stratified by treatment group. The study was conducted according to final Study Protocol from 14 Dec 2012, and included no substantial amendments.

5 14 Apr 2014 Study no Page: 4 of 6 Subject Disposition and Baseline Of the 40 subjects who were screened, no subjects were screening failures. Subsequently, 33 subjects were randomized to rivaroxaban treatment and 7 to UFH/Warfarin. There was an investigational site which committed the major GCP violation (falsification of data). The study team decided to remove all patients enrolled in this site from all analysis sets (ITT, ITT on treatment, safety, PP, ITT population for secondary efficacy variables and PP population for secondary efficacy variables) in the preliminary validity review meeting on 02 Oct Because source document couldn t be reliable. In 3 subjects, CUS and sct at baseline, Week 3 or the end of treatment were not conducted within the time frame (+/- 14 days) the planned date. These subjects were excluded from PP population, ITT population for secondary efficacy variables, and PP population for secondary efficacy variables. In 6 subjects, the thrombotic burden evaluations to be made at week 3 or at the end of treatment were done later than 10 days after the last intake of study medication. These subjects were excluded from PP population for secondary efficacy variables. Of the 33 subjects who received rivaroxaban, 15.2% (5/33) of the subjects had an intended treatment duration of 3 months, 48.5% (16/33) had an intended treatment duration of 6 months, and 36.4% (12/33) had an intended treatment duration of 12 months. Of the 7 subjects who received UFH/Warfarin, 14.3% (1/7) of the subjects had an intended treatment duration of 3 months, 42.9% (3/7) had an intended treatment duration of 6 months, and 42.9% (3/7) had an intended treatment duration of 12 months. Efficacy evaluation For ITT population, no recurrence of symptomatic VTE (composite endpoint of symptomatic DVT or symptomatic fatal or non-fatal PE) during the intended treatment was reported in both groups. The improvement in thrombotic burden was confirmed: - For the ITT population for secondary efficacy sets, the incidence rates of improvement at Week 3 were 96.3% (26/27 subjects) in the rivaroxaban group and 100% (7/7) in the UFH/warfarin group. The percentages of subjects with improvement in thrombotic burden at Week 3 for normalized were 14.8% (4/27) in the rivaroxaban group, and 0.0% (0/7) in the UFH/Warfarin group, respectively. The results in the ITT population were similar to that in the ITT population for secondary efficacy sets. - For the ITT population for secondary efficacy sets, the incidence rates of improvement at end of intended treatment period were 100% (27/27) in the rivaroxaban group and 85.7% (6/7) in the UFH/warfarin group. The percentages of subjects with improvement in thrombotic burden at the end of the treatment for normalized were 55.6% (15/27) in the rivaroxaban group, and 14.3% (1/7) in the UFH/Warfarin group, respectively. The results in the ITT population were similar to that in the ITT population for secondary efficacy sets. - For the ITT population for secondary efficacy sets, the incident rates of the composite of symptomatic VTE or asymptomatic deterioration of thrombus during the intended treatment period were 0.0% (0/27) in the rivaroxaban group and 14.3% (1/7) in the UFH/warfarin group. The results in the ITT population were similar to that in the ITT population for secondary efficacy sets. Two subjects in the rivaroxaban group and none in the UFH/Warfarin group had no recurrent VTE but no end of treatment scan available. Regarding the exploratory analysis, the incidence rates of the secondary efficacy variables (Part 2) were totally small and there was no obvious difference between two groups : - The incidence rates of the secondary efficacy outcome until the intended end of treatment were 6.7% (2/30) in the rivaroxaban group and 0% (0/7) in the UFH/Warfarin group for the ITT population (Difference to UFH/Warfarin: 6.7% [95%CI: -30.7% to 23.2%]). - The incidence rates of net clinical benefit 1 until the intended end of treatment were 3.3% (1/30) in the rivaroxaban group and 0% (0/7) in the UFH/Warfarin group for the ITT population (Difference to UFH/Warfarin: 3.3% [95%CI: -34.6% to 17.2%]).

6 14 Apr 2014 Study no Page: 5 of 6 - The incidence rates of net clinical benefit 2 until the intended end of treatment were 10.0% (3/30) in the rivaroxaban group and 0% (0/7)in the UFH/Warfarin group for the ITT population (Difference to UFH/Warfarin: 10.0% [95%CI: -27.0% to 26.2%]). Generally, the study showed consistency throughout the individual components of the primary efficacy outcome, intended treatment duration, demographics, baseline characteristics, and coagulation status. Since the absolute number of events was small, no general conclusion could be drawn based on the results of this study only. Safety evaluation The safety profile of rivaroxaban 15 mg od/bid was comparable to that of UFH/Warfarin. This conclusion is based on the following findings: The incidence rates of TEAEs were 90.0% (27/30 subjects) in the rivaroxaban group and 100% (7/7) in UFH/Warfarin group The incidence rates of drug-related TEAE were 50.0% (15/30) in the rivaroxaban group and 57.1% (4/7) in the UFH/Warfarin group There were 2 deaths reported in rivaroxaban group ( cardiac failure and shock haemorrhagic ). Causal relationships to study drug were denied. - On Day 2, the study drug was discontinued permanently due to liver enzymes elevation (ALT 55 U/L [baseline] to 305 U/L [Day 2]) and marketed warfarin and UFH started on that day for treatment of PE. On Day 5, gastrointestinal hemorrhage was observed. Marketed warfarin and UFH continued. On Day 10, the subject died due to shock hemorrhage. - On Day 21, the subject was hospitalized to the other hospital due to pneumonia and cardiac failure, and the study drug was discontinued permanently on Day 127, The subject died due to cardiac failure on Day 154. The incidence rates of SAEs were 23.3% (7/30) in the rivaroxaban group and 0.0% (0/7) in UFH/Warfarin group. - There were no drug-related TESAEs reported. The incidence rates of the treatment-emergent principle safety outcome based on the first event occurring were 3.3% (1/30) in the rivaroxaban group and 0.0% (0/7) in the UFH/Warfarin group (Difference to UFH/Warfarin: 3.3% [95%CI: -34.6% to 17.2%]). The incidence rates of major bleeding were 0.0% (0/30) in the rivaroxaban group and 0.0% (0/7) in the UFH/Warfarin group for the safety population (Difference to UFH/Warfarin: 0.0% [95%CI: -25.0% to 6.2%]). The incidence rates of non-major clinically relevant bleeding were 3.3% (1/30) in the rivaroxaban group and 0.0% (0/7) in the UFH/Warfarin group for the safety population (Difference to UFH/Warfarin: 3.3% [95%CI: -34.6% to 17.2%]). One clinically relevant non-major bleeding was observed for the skin (other than injection site) at 3.3% (1/30) in the rivaroxaban group. The incidence rates of all confirmed treatment-emergent bleeding events were 36.7% (11/30) in the rivaroxaban group and 57.1% (4/7) in the UFH/Warfarin group. During the on-treatment period, there was no cardiovascular event reported in both treatment groups. There were 5 subjects who showed ALT elevations >3 x ULN (rivaroxaban group: 13.3% [4/30], UFH/Warfarin group: 14.3% [1/7]). 20.0% (6/30) of the subjects in the rivaroxaban group had hepatic disorder AEs compared with 42.9% (3/7) subjects in the UFH/Warfarin group. No combined concurrent elevations of ALT >3 x ULN/total bilirubin >2 x ULN, AST >3 x ULN/total bilirubin >2 x ULN, ALT >3 x ULN/total bilirubin >2 x ULN/direct/total bilirubin 50%, and AST >3 x ULN and total bilirubin >2 x ULN/direct/total bilirubin 50%, (measurement from central laboratory) occurred in any treatment groups.

7 14 Apr 2014 Study no Page: 6 of 6 Overall conclusions Overall, the results of this study demonstrated that rivaroxaban 15 mg bid/od regimen (rivaroxaban 15 mg bid for a total of 3 weeks followed by rivaroxaban 15 mg od) was well tolerated in the treatment of PE and the prevention of the occurrence and the recurrence of DVT or PE in Japanese patients with acute symptomatic PE with or without symptomatic DVT. The numbers of each efficacy event is small in general. Almost all the subjects in both groups showed the improvement in thrombotic burden.

8 Appendix to Clinical Study Synopsis Product Identification Information Product Type US Brand/Trade Name(s) Brand/Trade Name(s) ex-us Generic Name Main Product Company Code Drug Xarelto Xarelto rivaroxaban BAY Other Company Code(s) Chemical Description Other Product Aliases IUPAC Name: 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4- morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide Date of last Update/Change: 04 Mar 2013

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

2. Background This indication of rivaroxaban had not previously been considered by the PBAC. PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of

More information

Gruppo di lavoro: Malattie Tromboemboliche

Gruppo di lavoro: Malattie Tromboemboliche Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant

More information

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NHS Evidence has accredited the process used

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

The importance of adherence and persistence: The advantages of once-daily dosing

The importance of adherence and persistence: The advantages of once-daily dosing The importance of adherence and persistence: The advantages of once-daily dosing Craig I. Coleman, PharmD Professor, University of Connecticut School of Pharmacy Storrs, CT, USA Conflicts of interest Dr

More information

Breadth of indications matters One drug for multiple indications

Breadth of indications matters One drug for multiple indications Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:

More information

Bios 6648: Design & conduct of clinical research

Bios 6648: Design & conduct of clinical research Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NICE has accredited the process used by the

More information

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction

More information

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78

More information

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach. Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight

More information

About the RECORD Clinical Trial Program

About the RECORD Clinical Trial Program About the RECORD Clinical Trial Program Fast facts RECORD was a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism

More information

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D. Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical

More information

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep

More information

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as

More information

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS

More information

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016

More information

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S. Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint

More information

Updates to the Alberta Human Services Drug Benefit Supplement

Updates to the Alberta Human Services Drug Benefit Supplement Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone

More information

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present

More information

Randomized, double-blind, parallel-group, multicenter, doubledummy

Randomized, double-blind, parallel-group, multicenter, doubledummy ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)

More information

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Updates to the Alberta Drug Benefit List. Effective January 1, 2016 Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)

More information

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013 Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013 General Principles: There is compelling data in the medical literature to support

More information

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,

More information

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012 EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial

More information

Anticoagulant therapy

Anticoagulant therapy Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in

More information

Indication: Indication: Protaxos is indicated in adults.

Indication: Indication: Protaxos is indicated in adults. Maklumat tambahan indikasi untuk upload pada laman web Year 2013 Products Approved For Additional Indication (DCA 262 28 Mac 2013) NO PRODUCT (ACTIVE INGREDIENT) 1. 1.1 EVISTA TABLET 60MG [ Raloxifene

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

CDEC RECORD OF ADVICE

CDEC RECORD OF ADVICE CDEC RECORD OF ADVICE RIVAROXABAN (Xarelto Bayer Inc.) Indication: Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism This document summarizes the Canadian Drug Expert Committee (CDEC) response

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications

More information

Implementation of NICE TAs 261 and 287

Implementation of NICE TAs 261 and 287 Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group Northampton General Hospital NHS Trust Northamptonshire Healthcare Foundation Trust Implementation

More information

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis. DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

More information

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Thrombosis and Hemostasis

Thrombosis and Hemostasis Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism

More information

The Role of the Newer Anticoagulants

The Role of the Newer Anticoagulants The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention

More information

Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip

Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre

More information

Australian Public Assessment Report for Rivaroxaban

Australian Public Assessment Report for Rivaroxaban Australian Public Assessment Report for Rivaroxaban Proprietary Product Name: Xarelto Sponsor: Bayer Australia Ltd October 2013 About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Therapeutic Class Overview Oral Anticoagulants

Therapeutic Class Overview Oral Anticoagulants Therapeutic Class Overview Oral Anticoagulants Therapeutic Class Overview/Summary: The oral anticoagulants, dabigatran etexilate mesylate (Pradaxa ), rivaroxaban (Xarelto ), and warfarin (Coumadin, Jantoven

More information

Cardiovascular Disease

Cardiovascular Disease Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage

More information

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart

More information

Rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery

Rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery for preventing venous thromboembolism after hip or knee replacement surgery (riv-ah-rocks-ah-ban) Summary Rivaroxaban is an oral anticoagulant and the first direct factor Xa inhibitor. Rivaroxaban has

More information

Patient Information Leaflet: Part 1 select-d

Patient Information Leaflet: Part 1 select-d Patient Information Leaflet: Part 1 select-d Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Introduction This

More information

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.

More information

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily

More information

National Guidance and New Protocols

National Guidance and New Protocols National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 DVT patient pathway Assessment Diagnosis

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

rivaroxaban 15mg and 20mg film-coated tablets (Xarelto ) SMC No. (852/13) Bayer plc

rivaroxaban 15mg and 20mg film-coated tablets (Xarelto ) SMC No. (852/13) Bayer plc rivaroxaban 15mg and 20mg film-coated tablets (Xarelto ) SMC No. (852/13) Bayer plc 08 February 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

More information

New Anticoagulants: When and Why Should I Use Them? Disclosures

New Anticoagulants: When and Why Should I Use Them? Disclosures Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia

More information

FDA Approved Oral Anticoagulants

FDA Approved Oral Anticoagulants FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic

More information

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban

More information

National Patient Safety Goals Effective January 1, 2015

National Patient Safety Goals Effective January 1, 2015 National Patient Safety Goals Effective January 1, 2015 Goal 1 Improve the accuracy of resident identification. NPSG.01.01.01 Long Term are ccreditation Program Medicare/Medicaid ertification-based Option

More information

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime

More information

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:

More information

SYNOPSIS. Risperidone: Clinical Study Report CR003274

SYNOPSIS. Risperidone: Clinical Study Report CR003274 SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:

More information

Xarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason

Xarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical

More information

National Guidance and New Protocols

National Guidance and New Protocols National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 Autumn dawn Restless geese take flight

More information

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

Title Use of rivaroxaban in suspected DVT in the Emergency Department Standard Operating Procedure. Author s job title. Pharmacist.

Title Use of rivaroxaban in suspected DVT in the Emergency Department Standard Operating Procedure. Author s job title. Pharmacist. Document Control Title Use of rivaroxaban in suspected DVT in the Emergency Department Author Pharmacist Directorate Clinical Support Services Version Date Issued Status 0.1 Oct Draft 2015 1.0 Dec Final

More information

To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.

To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients. UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 March 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 March 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 ARIXTRA 1.5 mg/0.3 ml, solution for injection in pre-filled syringe Box of 2 (CIP: 363 500-6) Box of

More information

National Patient Safety Goals Effective January 1, 2015

National Patient Safety Goals Effective January 1, 2015 National Patient Safety Goals Goal 1 Nursing are enter ccreditation Program Improve the accuracy of patient and resident identification. NPSG.01.01.01 Use at least two patient or resident identifiers when

More information

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis

More information

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Appendix C Factors to consider when choosing between anticoagulant options and FAQs Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened

More information

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism This guidance was developed using

More information

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning

More information

East Kent Prescribing Group

East Kent Prescribing Group East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal

More information

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71 Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.

More information

PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN,

PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015 Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents

More information

NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM

NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin

More information

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser Acute Sector NHS Grampian Staff Local Treatment Protocol For Venous Thromoboembolic Prophylaxis Using Rivaroxaban 10mg Tablets In Adult Patients Undergoing Elective Hip Or Knee Replacement Surgery. Lead

More information

The University of Mississippi Medical Center. Pharmacy and Therapeutics Committee Anticoagulation Medication Use Evaluation Lindsey Tillman, Pharm.D.

The University of Mississippi Medical Center. Pharmacy and Therapeutics Committee Anticoagulation Medication Use Evaluation Lindsey Tillman, Pharm.D. The University of Mississippi Medical Center Pharmacy and Therapeutics Committee Anticoagulation Medication Use Evaluation Lindsey Tillman, Pharm.D. Purpose This medication use evaluation (MUE) is a retrospective

More information

Dabigatran (Pradaxa) Guidelines

Dabigatran (Pradaxa) Guidelines Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without

More information

Licence for use in the UK is expected before the end of 2011

Licence for use in the UK is expected before the end of 2011 News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval

More information

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms

More information

Rivaroxaban (Xarelto) in the management of stroke and DVT

Rivaroxaban (Xarelto) in the management of stroke and DVT Rivaroxaban (Xarelto) in the management of stroke and DVT Steve Chaplin MSc, MRPharmS, Victoria Haunton BM, DGM, MRCP, Thompson Robinson BMedSci, MD, FRCP and Catherine Bagot MD, FRCPath KEY POINTS is

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012

More information

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment

More information

Time of Offset of Action The Trial

Time of Offset of Action The Trial New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About

More information